Gujarat Kidney And Super Speciality working capital

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026
82.29×82.29×
171.92×171.92×
338.62×338.62×
−84.41×−84.41×
1.32×1.07×
0.28×0.28×
−0.23×−0.23×
−0.14×−0.14×
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

GKSL₹171.87

Gujarat Kidney And Super Speciality Limited

· Pharma & Health
₹ CrorePeersGPTHEALTHSHALBYINDRAMEDCOLOTUSEYEARTEMISMEDDRAGARWQKMCSHILKOVAIMcap ₹1,355 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)82.2982.29
Receivable Days (DSO)171.92171.92
Payable Days (DPO)338.62338.62
Cash Conversion Cycle (days)-84.41-84.41
Working Capital Turnover1.071.32
Asset Turnover0.280.28
Cash Conversion (CFO/Net Income)-0.23-0.23
CFO/EBITDA-0.14-0.14
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.